Focus: Oxford Drug Design is a UK-based biotechnology company specializing in antibiotic drug discovery and infectious disease therapeutics. The company operates primarily in the generics and specialty pharmaceutical space with a portfolio of established small-molecule products.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Oxford Drug Design to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multi-indication mature generic with post-LOE status, generating cash but facing ongoing market erosion.
Help build intelligence for Oxford Drug Design
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Oxford Drug Design's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Established diuretic in post-LOE phase; standard-of-care but commoditized in competitive hypertension market.
Mature statin with post-LOE status facing intense generic competition and newer agent displacement.
Established anticonvulsant with broad epilepsy franchise but in post-LOE decline.
Older antiplatelet agent facing displacement by newer anticoagulants and antiplatelet therapies.
14 discontinued, 20 duplicate formulations not shown
+11 more products
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo